INTRODUCTION
Over the past 30 years we have seen vast improvements in the survival of cystic fibrosis (CF) patients. This has resulted in increasing numbers of patients with CF graduating into adult clinics. Median survival of up to 30 years has been reported from centres in Canada and the USAI-3 and Elborn and colleagues estimated a median life expectancy of 40 years for British CF children born in 19904. It is important to recognize that such advances in survival came before the discovery of the gene, and knowledge of its protein product, the Cystic Fibrosis Transmembrane Regulator (CFTR). Furthermore, increased survival predated the introduction of recombinant human DNase (rhDNase). It has been suggested that differences in survival between countries relate to different approaches to antibiotic therapy, infection control policies and nutritional support1l5. The different survival patterns are difficult to explain on the basis of one single treatment variable but it behoves us to consider our approach and attention to the detail of the basics of treating adults with physiotherapy, antibiotics and nutritional support. Consideration needs to be given to the evaluation of new treatments against the background of current best practice and current best outcomes.
GOALS OF TREATMENT
The goals of treating CF adults (Table 1) have changed considerably as survival has improved. Twenty years ago treatment was aimed at maintaining what was left of a very diseased lung. Today not only do we seek to prevent deterioration in lung function, but the possibility of improving lung function should be considered in any adult patient. The clinical trials of rhDNase treatment were the first in CF to show an improvement in pulmonary function rather than a reduction in decline of FEV16. The importance of considering the effect of a new treatment over current best practice is highlighted in the differences between two studies of a nebulized amiloride therapy7'8. One study in which usual antibiotic therapy was discontinued showed a reduction in decline of lung function in the amiloride treated group compared to placebo7, whereas the UK study in which optimal therapy was continued showed no such difference8. Furthermore, patients felt no symptomatic benefit from amiloride therapy, hence it did not gain momentum as an adjunct to usual treatment in adult clinics. Our goals of treatment now include improved quality of life in an adult population in whom the majority are actively engaged in full-time education or employment. With this in mind, patients will expect a new treatment to add little to their daily burden of treatment, whilst adding considerably to their general well-being.
ATTENTION TO DETAIL
It has been reported that lung function declines by 3-4% annually in patients with established pulmonary infection9. This was certainly the case in the placebo group in the recent trial of high dose ibuprofenl0. However, the previously reported inevitable decline should not lead to complacency regarding treatment in the adult CF patient. The introduction of rhDNase into our practice has reset the thinking on decline of pulmonary function as the report of follow-up at 24 months shows that the initial improvement in FEV1 of 1 3% levels out at about 7. 1%, but is maintained at 24 monthsl 1. The response to rhDNase is variable, but it suggests that previous reported rates of annual decline may no longer be appropriate. We have recently analysed data from our short experience since the inception of the Adult CF clinic at Papworth in 1994. As there was previously no large CF centre in East Anglia, the patients referred within the first two years, on the whole had not received 'large centre' care previously. Indeed a significant proportion had been looked after at District General Hospitals, by Consultant Chest Physicians with an interest in CF, or from small paediatric units. Eighty patients were referred between 1994 and 1996, of which 55 were men. The mean age at referral was 22.6 years. The mean % ( SE) predicted FEV1 was 44.2% (+2.72), and mean (±SE) predicted FVC was 60% + 2.6%. These figures suggest that we had been referred a group of patients with relatively severe disease which was not unexpected for a new centre. Five patients died within 12 months of referral and 5 patients received heart/lung transplantation. Data is available on a cohort of 53 patients who have now received at least 12 months follow-up at the Papworth Adult CF Centre. The mean ( ± SE) FEV1% predicted for this group at referral was 46.7% (+ 3.6) and at 12 months follow-up was 48.2% (± 3.7). This slight improvement just failed to reach significance (P=0.05 1). The % predicted FVC at referral was 62% (+ 3.3) and at 12 months follow up had risen to 65.1% (+ 3.3). This modest increase did reach significance (P< 0.05). The maintenance, and suggestion of slight improvement cannot be attributed to one single factor. Each patient at referral had their basic treatment of physiotherapy, antibiotic therapy and nutritional status reviewed and a plan produced for their care. Twenty patients were started on prophylactic nebulized antibiotics for Pseudomonas colonization having not previously received this therapy and 10 patients had their first course of intravenous antibiotics at Papworth recommended as a 'tune-up' to maximize lung function before recommending further prophylactic treatment. Other adjustments to therapy included the introduction of regular bronchodilators, either salbutamol alone, or in combination with ipatropium bromide, introduced on the basis of lung function testing. As patients are referred from such different backgrounds of care, our policy is to maximize lung function with basic therapy before entering a patient into their own trial of therapy with rhDNase. Another confounding factor may be that in the first 12 months at a new centre, patients are more enthusiastic and compliant and this may contribute to the lack of decline in lung function. Nevertheless the suggestion that lung function in adults can be improved is a concept that 10 years ago would have seemed unattainable.
an adult clinic patients themselves will take a lead in making the decision, depending on their perception of the intrusion of a two week course of home i.v.'s on their life compared to the benefits accrued.
Nebulized antibiotics have been shown to maintain lung function between courses of antibiotics and are in widespread use as prophylaxis in adult clinics. The most recent well controlled study showed an improvement in lung function during high dose aerosolized tobramycin with a concomitant decrease in sputum density of Pseudomonas aeruginosa. The drawback of this study was that patients had to receive 600mg of aerosolized tobramycin three times a day, which involved a 30 ml volume of nebulization12. It is unlikely that compliance with such therapy would be maintained.
NEW THERAPEUTIC APPROACHES

Treating the host response to infection
The progression of pathogenic events arising from the gene mutation is now much better understood because of increasing understanding ofthe CF transmembrane regulator. In addition furthermore studies relating to gene therapy have allowed us to understand that P. aeruginosa is more likely to adhere to CF respiratory epithelium than normal cells12. The focus for new therapy in adults with established pulmonary infection and associated inflammation is likely to centre around agents which modify airway secretions and interrupt the vicious cycle of damage to the lung which is orchestrated by the neutrophil response to infection (Fig. 1) .
The principle of using prednisolone to dampen down the host response was first studied in the 1 980s and CF gene mutations The debate continues around the world regarding the best approach for the use of intravenous antibiotics for patients colonized with Pseudomonas. Some centres advocate that patients should receive a two week course every three months while other centres suggest that patients should be treated with intravenous antibiotics on an exacerbation only basis. The Danish centre claims that the aggressive approach which includes three monthly intravenous therapy is partly responsible for the improved survival from this centre5. In Recently in a multi-centre study in America 1 mg/kg of prednisolone on alternate days or 2mg/kg alternate days was compared with placebo14.
The study was planned to run over 4 years. The decline in lung function in the 2 mg/kg group was significantly less than the decline in lung function seen in the placebo group. However, treatment in the 2 mg/kg group was discontinued at 2 years because of unacceptable steroid effects, particularly growth failure. In the 1 mg/kg group there was a significant benefit in terms of maintenance of lung function, but there was still an unacceptable level of steroid side effects. It is interesting that in the 2 mg/kg group the effect on lung function was no different from placebo at 24 months. This may relate to a higher incidence of Pseudomonas colonization in this group compared to the 1 mg/kg group, but it may also indicate that there is a balance between host response and bacteria which when pushed too far in the direction of immunosuppression is not helpful. However, the evidence from this study suggests that anti-inflammatory treatment is of benefit to the lungs. A rational approach would be to carry out a long term study of inhaled steroids. Many adult CF patients are already on inhaled steroids because of a clinical diagnosis of concomitant asthma. We do not have sufficient long term study data to suggest that all adult CF patients should be treated with inhaled steroids at present but such a study should be performed.
In an effort to find another anti-inflammatory therapy with perhaps a more acceptable side effect profile, Konstan and colleagues carried out a well constructed study looking at the effect of ibuprofen on lung function10. Eighty-five patients were studied between the ages of 5 and 39, all of whom had a starting FEVI, annual rate of change of FVC, and annual rate of change of RV/TLC. Patients were randomized to receive ibuprofen or placebo, twice daily for 4 years and doses were adjusted to maintain a plasma level of between 50 and 100 gml-1. Such plasma monitoring was required to ensure that an anti-inflammatory effect was obtained as a low dose may be pro-inflammatory. There was a significant reduction in the decline of lung function in the treated group but a particularly marked benefit in the patient under the age of 13 with particularly mild lung disease. The clinician still faces many questions about when to introduce what may be considered as yet 'second-line' therapy. Will ibuprofen in high dosage be as effective or more effective than inhaled steroids, DNase or any other 'new' therapy?
ANTI-ELASTASE THERAPY
Rationale and early studies Several recent studies have indicated that there is a very are high levels of neutrophil elastase released as the bacterial load persists and neutrophils are frustrated in their ability to phagocytose the organisms. Elastase has many deleterious effects on respiratory epithelium, but also reduces the ability of the immune system to opsonize and phagocytose bacteria17'18. In addition elastase induces IL8 secretion from respiratory epithelial cells. As IL8 is chemoattractant for neutrophils the vicious cycle continues. Konstan et al. performed lavage in clinically well, stable adult patients and found high levels of neutrophils in the lung and significant levels of free elastase19. Thus there is persistent inflammation and injury even when we might consider a patient clinically stable. Elastase is normally inactivated by the anti-protease ail-anti-trypsin. There is no absolute deficiency of cl-anti-trypsin in CF but it seems that the burden of elastase overwhelms the ability of the anti-protease screen to cope, resulting in a relative deficiency and an imbalance in favour of lung damage.
With the availability of plasma derived al-anti-trypsin developed to treat a1-anti-trypsin deficient patients a study was designed to look at the effects of delivering nebulized al-anti-trypsin to CF patients20. This first study was carried out over one week with nebulized ac-anti-trypsin delivered twice daily. Lavage was performed at the beginning and end of the study. The results of this preliminary study showed that nebulizing al-anti-trypsin raised the levels of o1-anti-trypsin in the lavage fluid and furthermore reduced the amount of free elastase. There were no clinical end points to this study. The problem of supply of plasma derived ac-anti-trypsin has resulted in developments of alternative sources. Advances in molecular biology techniques have allowed the production of transgenic sheep which secrete human a -anti-trypsin in their milk. Clinical trials with this product are planned for 1997. Other workers have looked at the effect of other antiproteases, including recombinant secretory leukoprotease inhibitor which has also been shown to reduce the elastase burden21.
An alternative approach is to modulate the activity of the cells which orchestrate the inflammatory response. The drug pentoxifylline has been studied, which decreases the activity of TNFoa, and reduces neutrophil adhesiveness and degranulation. It has been shown in a short term study to reduce sputum elastase and improve lung function22.
EVALUATION OF NEW THERAPIES
It is exciting that there are now so many new avenues to treatment with early clinical trials being developed for antielastase, anti-neutrophil, and anti-cytokine therapies. The problem arises in translating such trials into clinical practice. For the patients there is already a considerable early inflammatory response in CF lung disease15'16. There Sup p le me nt No. 3 1 Vo u me 90 1 997 burden of treatment for those with established lung infection and inflammation. The burden of simply carrying out physiotherapy, nebulization and exercise each day can add up to 2 h. The addition of further nebulized treatment aimed at preventing decline of lung function, but without any particular effect on the patient's symptoms, may be difficult for young busy adults to accept. Problems already encountered with rhDNase are in deciding when to introduce a new treatment and how to evaluate its effect in each individual. Questions, such as whether nebulized antibiotics should be firmly established in a patient's treatment regime before the addition of rhDNase or not remains unanswered. It is therefore important in considering the future of treatment for adults that we look to therapies which encompass all the goals of treatment already mentioned. It is crucial that in attempting to improve lung function and prolong survival that we do not tie up our patients into hours of therapy which may have a detrimental effect on the quality of life merely because of the burden of treatment. Clearly the long term aim is to try and prevent the vicious cycle of inflammation, infection and lung injury ever developing. The hope is that gene therapy or pharmacological manipulation of the CFTR protein would enable us to normalize the environment of the lung to prevent Pseudomonas colonization. Whilst this remains a future hope it is important that we build up our armoury of treatments for those with established bronchiectasis. In addition we must remember that survival has improved with the introduction of close attention to detail in terms of antibiotic therapy, physiotherapy, nutritional advice, and pancreatic supplementation. We must continue to ensure that patients receive optimum treatment along these lines before adding in new and potentially expensive therapies.
